tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

SNYNF Stock Latest News

Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Asthma Treatment
Company AnnouncementsRegeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Asthma Treatment
1h ago
SNY
REGN
Sanofi’s New Study Aims for Early Detection of Type 1 Diabetes in At-risk Youth
PremiumCompany Announcements
Sanofi’s New Study Aims for Early Detection of Type 1 Diabetes in At-risk Youth
1h ago
SNY
Sanofi’s New Study on Isatuximab Combination Therapy for Multiple Myeloma Shows Promise
PremiumCompany Announcements
Sanofi’s New Study on Isatuximab Combination Therapy for Multiple Myeloma Shows Promise
1h ago
SNY
Sanofi’s Promising Amlitelimab Study: A Potential Game-Changer for Atopic Dermatitis
PremiumCompany Announcements
Sanofi’s Promising Amlitelimab Study: A Potential Game-Changer for Atopic Dermatitis
1h ago
SNY
Sanofi’s Promising SLE Treatment Study: A Potential Game-Changer?
PremiumCompany Announcements
Sanofi’s Promising SLE Treatment Study: A Potential Game-Changer?
1h ago
SNY
Regeneron and Sanofi’s Dupilumab Trial: A Potential Game-Changer for Ulcerative Colitis
PremiumCompany AnnouncementsRegeneron and Sanofi’s Dupilumab Trial: A Potential Game-Changer for Ulcerative Colitis
1h ago
SNY
REGN
Sanofi’s Promising Phase 3 Study on Amlitelimab for Atopic Dermatitis
Premium
Company Announcements
Sanofi’s Promising Phase 3 Study on Amlitelimab for Atopic Dermatitis
1h ago
SNY
Sanofi’s SAR446268 Gene Therapy Study: A Potential Game-Changer for Myotonic Dystrophy
Premium
Company Announcements
Sanofi’s SAR446268 Gene Therapy Study: A Potential Game-Changer for Myotonic Dystrophy
2h ago
SNY
Trump, pharma industry discuss increasing medicine spending abroad, Reuters says
PremiumThe Fly
Trump, pharma industry discuss increasing medicine spending abroad, Reuters says
4h ago
AZN
BMY
Sanofi upgraded to Overweight from Neutral at JPMorgan
PremiumThe Fly
Sanofi upgraded to Overweight from Neutral at JPMorgan
9h ago
SNY
Sanofi’s Phase 3 Study on Tolebrutinib: A Potential Game-Changer for Multiple Sclerosis
PremiumCompany Announcements
Sanofi’s Phase 3 Study on Tolebrutinib: A Potential Game-Changer for Multiple Sclerosis
1d ago
SNY
Sanofi’s SAR443579 Study Terminated: Implications for Hematological Cancer Treatment
PremiumCompany Announcements
Sanofi’s SAR443579 Study Terminated: Implications for Hematological Cancer Treatment
1d ago
SNY
Sanofi’s Promising Phase 2 Study on Crohn’s Disease Treatment
PremiumCompany AnnouncementsSanofi’s Promising Phase 2 Study on Crohn’s Disease Treatment
1d ago
SNY
Sanofi’s Teplizumab Study in Japan: A Potential Game-Changer for Type 1 Diabetes
Premium
Company Announcements
Sanofi’s Teplizumab Study in Japan: A Potential Game-Changer for Type 1 Diabetes
1d ago
SNY
Sanofi’s New Asthma Treatment Study: Potential Market Game-Changer
Premium
Company Announcements
Sanofi’s New Asthma Treatment Study: Potential Market Game-Changer
1d ago
SNY
Sanofi’s New Phase 3 Study: A Potential Game-Changer in Type 1 Diabetes Treatment
PremiumCompany Announcements
Sanofi’s New Phase 3 Study: A Potential Game-Changer in Type 1 Diabetes Treatment
1d ago
SNY
Sanofi’s Asthma Study: A Long-term Look at Lunsekimig’s Potential
PremiumCompany Announcements
Sanofi’s Asthma Study: A Long-term Look at Lunsekimig’s Potential
1d ago
SNY
Regeneron and Sanofi’s Phase 3 Itepekimab Study: A Potential Game Changer for CRSwNP Treatment
PremiumCompany Announcements
Regeneron and Sanofi’s Phase 3 Itepekimab Study: A Potential Game Changer for CRSwNP Treatment
1d ago
SNY
REGN
Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Pediatric Asthma
PremiumCompany Announcements
Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Pediatric Asthma
1d ago
SNY
REGN
Sanofi’s SAR444881 Study Terminated: Implications for Investors
PremiumCompany AnnouncementsSanofi’s SAR444881 Study Terminated: Implications for Investors
1d ago
SNY
Regeneron and Sanofi’s DUPIXENT® Study: A Boost for EoE Treatment Insights
Premium
Company Announcements
Regeneron and Sanofi’s DUPIXENT® Study: A Boost for EoE Treatment Insights
1d ago
SNY
REGN
Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Lichen Simplex Chronicus
Premium
Company Announcements
Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Lichen Simplex Chronicus
1d ago
SNY
REGN

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >